Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Opthea ( (AU:OPT) ).
Opthea Limited has announced its decision to voluntarily delist from the Nasdaq Stock Market while maintaining its listing on the Australian Securities Exchange (ASX). This strategic move is aimed at streamlining operations, reducing costs, and focusing on the Australian market to enhance long-term shareholder value. The company plans to continue its American Depositary Receipt program to facilitate trading for U.S. investors in the OTC market, aligning its structure with operational priorities.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is a biopharmaceutical company focused on developing novel therapies to treat diseases mediated by Vascular Endothelial Growth Factors (VEGF) C and/or D.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
For detailed information about OPT stock, go to TipRanks’ Stock Analysis page.